Eloralintide
25% off when buying 10+ items (any product)
ELORA | 5MG
SELECTIVE AMYLIN RECEPTOR RESEARCH PEPTIDE
Explore the next frontier of metabolic signaling.
Product Overview
At Origin.1, we believe meaningful advances in metabolic science begin with understanding the body’s natural communication pathways. Eloralintide (ELORA) is an investigational peptide designed to selectively engage amylin receptors, offering a distinct avenue for the study of satiety, appetite regulation, and energy balance.
Presented as a 5MG lyophilized research peptide, ELORA is intended for laboratory investigation into how amylin-mediated signaling influences nutrient responses and body-weight regulation. Its mechanism differs from GLP-1, GIP, and glucagon receptor agonism.
The Science Behind Eloralintide
Selective AMY1 Receptor Signaling
Amylin is a hormone secreted by pancreatic beta cells alongside insulin in response to food intake. It contributes to communication between the digestive system and the brain, helping regulate meal-related fullness and food intake.
Eloralintide (also known as LY3841136) is an investigational long-acting selective amylin receptor agonist developed to preferentially activate the amylin 1 receptor (AMY1R). This targeted pharmacology is being studied for its effects on appetite, weight regulation, and cardiometabolic outcomes.
A Distinct Research Pathway
Unlike incretin-based compounds that primarily engage GLP-1 or GIP receptors, eloralintide targets amylin signaling. This makes it scientifically valuable for examining a separate, complementary endocrine pathway involved in energy intake.
Key Research Areas
Satiety and fullness signaling: Investigation of amylin-related communication influencing the sensation of fullness after meals.
Appetite and food-intake regulation: Study of how AMY1R activity affects hunger-related signaling and meal size.
Body-weight research: Evaluation of the relationship between selective amylin receptor activation and changes in body weight.
Cardiometabolic regulation: Exploration of metabolic markers associated with altered food intake and body-weight trajectories.
Receptor selectivity: Comparative research into AMY1R activation and the effects of receptor-selective peptide design.
What Current Research Shows
In a published 48-week randomized Phase 2 study in adults with obesity or overweight and a weight-related comorbidity, investigational eloralintide produced dose-dependent average reductions in body weight. The results belong to the clinical-trial formulation and do not establish the quality, safety, or performance of any third-party research vial.
Gastrointestinal symptoms and fatigue were among reported adverse events in clinical studies. Eloralintide remains investigational; long-term safety and optimal clinical use are not established.
The Origin.1 Philosophy
Restore What Was Always There.
The body’s metabolic signaling systems are interconnected and remarkably complex. ELORA represents an opportunity to study one of these systems through targeted amylin receptor research—advancing knowledge of how biological communication shapes appetite and metabolic adaptation.
ORIGIN.1 — BUILD. ADAPT. BECOME.
Product Specifications
Product | Eloralintide (ELORA) |
Labeled content | 5MG |
Compound | Eloralintide / LY3841136 |
Physical form | Lyophilized peptide |
Primary research target | Selective amylin receptor agonism (AMY1R) |
Research focus | Satiety, appetite and metabolic signaling |
Intended purpose | Laboratory research only |
Research Use Disclaimer
NOT FOR HUMAN CONSUMPTION | RESEARCH USE ONLY. Eloralintide is an investigational compound and is not FDA-approved as of October 2026. This product description is for scientific information only and makes no claim that this research material is equivalent to compounds used in clinical trials. Any purity or identity claim should be supported by batch-specific analytical documentation.
